Have you ever looked at Biocon in the generic space? I believe market cap is about $1B and they seem to be one of the few small/mid-cap names that is pursuing the generic insulin analog market (partnered with MYL), which is presumably going to be a huge market in due time. I'm not sure if PLX or MNTA are pursuing this space.
Market Data 
Markets 
AI
